Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 7, 2020 (7 years ago)

Desmopressin Acetate Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

GMP Deviations: Product bottle may be absent of desiccant.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Desmopressin Acetate Tablets, 0.2 mg, 30 tablets (3 x 10 unit dose blister cards), Rx Only, Packaged and distributed by: American Health Packaging, Columbus, Ohio 43217. NDC Carton: 68084-604-21; NDC Unit Dose 68084-604-11

Affected NDCs 68084-0604-11 68084-0604-21

Compare with the code on your package — it is the most precise check available.

Drug: Desmopressin

Recalling firm
American Health Packaging
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0849-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Desmopressin recalls

See all
Class II · Moderate risk

Desmopressin Nasal Spray

Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.

Ongoing Packaging defect Apotex Corp. NDC 60505-0815-0 D-0510-2026
Class II · Moderate risk

Desmopressin Acetate Injection USP

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

Terminated Sterility / contamination Teva Pharmaceuticals USA NDC 0703-5051-01 D-0272-2021

Other recalls by American Health Packaging

All 2020 recalls
Class III · Low risk

Nitrofurantoin Capsules

Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

Terminated Dissolution failure American Health Packaging NDC 68084-446-11 D-0880-2022